Cervical Cancer Vaccine: Serum Institute of India's vaccine against cervical cancer will be available in the market this month. The name of this vaccine is 'CERVAVAC', which has been manufactured in India. The cost of a two-dose vial of this vaccine will be Rs 2000. Official sources have given this information.
Union Home Minister Amit Shah launched the first 'Made-in India' last month i.e. on January 24 in the presence of Adar Poonawalla, Chief Executive Officer (CEO) of Serum Institute of India and Prakash Kumar Singh, Director, Government and Regulatory Affairs, SII. The Human Papillomavirus vaccine was released.
According to a PTI report, an official source, Prakash Kumar Singh has said in a letter to the Health Ministry that a vial containing two doses of his HPV vaccine would cost Rs 2000 in the private market. This price is much less than the rest of the HPV vaccines. Many hospitals and doctors are demanding this HPV vaccine. Serum Institute will start supplying Cervavac in the private market this month itself.
India is currently dependent on foreign manufacturers
It has been told that Prakash Singh has also said in his letter that whenever the Health Ministry wants to buy the HPV vaccine, the Serum Institute will make it available at very affordable prices. India is currently completely dependent on foreign vaccine manufacturers for the HPV vaccine. Right now only the Gardasil HPV vaccine of America's multinational company Merck is available in the private market and its price is Rs.10,850.
80 thousand women get cervical cancer every year
It is the effort of the Indian Health Ministry to start applying the HPV vaccine to girls aged 9 to 14 in June under the National Vaccination Drive so that the risk of cervical cancer can be reduced. It is known that about 16 percent of the world's female population resides in India. 25 percent of cervical cancer cases come in India. According to some recent estimates, about 80,000 women in India are diagnosed with cervical cancer every year and about 35,000 women die due to it.